Skip to content
Screener

Incyte INCY Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.34B-12.2%
Pfizer logo
PfizerPFE
$14.2B+6.8%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$3.11M+22.4%
Gilead Sciences logo
Gilead SciencesGILD
$1.49B+15.5%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$240K+138%
AbbVie logo
AbbVieABBV
$34.11B+9.4%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24B+58.2%
Enterprise value$20.05B+51.3%
P/E14.9×-2.5×
P/S4.1×+0.8×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemJune 30,2026December 31,2025*
Total current liabilities1,312,0961,515,170
Acquisition-related contingent consideration63,18979,856
Finance lease liabilities28,42030,199
Other liabilities124,515165,270
Total liabilities1,528,2201,790,495
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding

Item 1. Financial Statements

FAQ

What is Incyte's other non-current liabilities?
Incyte (INCY) reported other non-current liabilities of $124.52M in Q2 2026.
How has Incyte's other non-current liabilities changed year-over-year?
Incyte's other non-current liabilities decreased by 30.8% year-over-year, from $179.91M to $124.52M.
What is the long-term trend for Incyte's other non-current liabilities?
Over 5 years (2020 to 2025), Incyte's other non-current liabilities has grown at a 23.2% compound annual growth rate (CAGR), from $58.28M to $165.27M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Incyte's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude